Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Black Diamond Therapeutics (BDTX) Equity Ratio (2018 - 2025)

Black Diamond Therapeutics (BDTX) has disclosed Equity Ratio for 3 consecutive years, with 0.8 as the latest value for Q3 2021.

  • For the quarter ending Q3 2021, Equity Ratio fell 15.47% year-over-year to 0.8, compared with a TTM value of 0.8 through Sep 2021, down 15.47%, and an annual FY2020 reading of 0.93, up 413.37% over the prior year.
  • Equity Ratio was 0.8 for Q3 2021 at Black Diamond Therapeutics, down from 0.87 in the prior quarter.
  • Across five years, Equity Ratio topped out at 0.98 in Q2 2020 and bottomed at 0.3 in Q4 2019.
  • Average Equity Ratio over 3 years is 0.76, with a median of 0.91 recorded in 2021.
  • The sharpest move saw Equity Ratio surged 413.37% in 2020, then dropped 15.47% in 2021.
  • Year by year, Equity Ratio stood at 0.3 in 2019, then soared by 413.37% to 0.93 in 2020, then decreased by 14.44% to 0.8 in 2021.
  • Business Quant data shows Equity Ratio for BDTX at 0.8 in Q3 2021, 0.87 in Q2 2021, and 0.9 in Q1 2021.